Experts Discuss CELMoD Agents for Multiple Myeloma

In this podcast episode, Meletios-Athanasios (Thanos) C. Dimopoulos, MD, and María-Victoria Mateos, MD, PhD, as they discuss the use of CELMoD agents to manage multiple myeloma, including:  - The recent FDA approval of iberdomide - Mechanism of action and differentiation from IMiDs - Current data and potential treatment settings **Presenters:** **Meletios-Athanasios (Thanos) C. Dimopoulos, MD** Professor and Chairman Plasma Cell Dyscrasias Unit Section of Hematology and Medical Oncology Department of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Alexandra Hospital Athens, Greece **María-Victoria Mateos, MD, PhD** Myeloma Unit, Director Professor of Medicine University Hospital of Salamanca Salamanca, Spain Content based on an online CME program supported by an educational grant from Bristol Myers Squibb. Link to full program: https://bit.ly/4xgnHri Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.